Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost
New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma or
Study of TRAVATAN in Subjects With Iris Pigmentation Changes
The purpose of this study was to monitor iris pigmentation changes over a 5-year period in
patients with open-angle glaucoma or ocular hypertension. To be eligible for the study, these
individuals must have experienced an iris pigmentation change while previously dosing with
Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic
Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle
glaucoma (OAG) or ocular hypertension (OHT).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.